Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:OCX

OncoCyte (OCX) Stock Price, News & Analysis

OncoCyte logo

About OncoCyte Stock (NASDAQ:OCX)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
$2.60
$3.44
52-Week Range
N/A
Volume
100,514 shs
Average Volume
58,260 shs
Market Capitalization
$90.80 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.06
Consensus Rating
Moderate Buy

Company Overview

OncoCyte Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
27th Percentile Overall Score

OCX MarketRank™: 

OncoCyte scored higher than 27% of companies evaluated by MarketBeat, and ranked 828th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    OncoCyte has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    OncoCyte has received no research coverage in the past 90 days.

  • Read more about OncoCyte's stock forecast and price target.
  • Earnings Growth

    Earnings for OncoCyte are expected to grow in the coming year, from ($2.57) to ($1.40) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of OncoCyte is -0.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of OncoCyte is -0.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Short Interest

    There is no current short interest data available for OCX.
  • Dividend Yield

    OncoCyte does not currently pay a dividend.

  • Dividend Growth

    OncoCyte does not have a long track record of dividend growth.

  • Short Interest

    There is no current short interest data available for OCX.
  • Search Interest

    2 people have searched for OCX on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, OncoCyte insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 2.05% of the stock of OncoCyte is held by insiders.

  • Percentage Held by Institutions

    55.35% of the stock of OncoCyte is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about OncoCyte's insider trading history.
Receive OCX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for OncoCyte and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

OCX Stock News Headlines

Trump’s national nightmare is here
Porter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger the biggest forced rotation of capital since World War II. They reveal why Trump is mobilizing America’s tech giants… and name the two stocks most likely to soar as trillions shift behind the scenes.tc pixel
See More Headlines

OCX Stock Analysis - Frequently Asked Questions

OncoCyte Corporation (NASDAQ:OCX) posted its quarterly earnings data on Monday, May, 12th. The company reported ($0.26) earnings per share for the quarter, missing analysts' consensus estimates of ($0.24) by $0.02. The company had revenue of $2.14 million for the quarter, compared to the consensus estimate of $0.13 million. OncoCyte had a negative net margin of 1,516.06% and a negative trailing twelve-month return on equity of 215.59%.
Read the conference call transcript
.

OncoCyte's stock reverse split on Tuesday, July 25th 2023.The 1-20 reverse split was announced on Tuesday, July 25th 2023. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, July 25th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

OncoCyte's top institutional shareholders include Defender Capital LLC. (0.12%). Insiders that own company stock include Broadwood Partners, LP, Pura Vida Investments, Llc, Andrea S James, Andrew Arno, Alfred D Kingsley and Josh Riggs.
View institutional ownership trends
.

Based on aggregate information from My MarketBeat watchlists, some other companies that OncoCyte investors own include Alibaba Group (BABA), Meta Platforms (META), Fulcrum Therapeutics (FULC), VBI Vaccines (VBIV), Sorrento Therapeutics (SRNE), CymaBay Therapeutics (CBAY) and Ford Motor (F).

Company Calendar

Last Earnings
5/12/2025
Today
8/29/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Medical Services
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:OCX
CIK
1642380
Employees
120
Year Founded
N/A

Price Target and Rating

High Price Target
$8.00
Low Price Target
$4.00
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
4 Analysts

Profitability

EPS (Trailing Twelve Months)
($3.53)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$60.66 million
Net Margins
-1,516.06%
Pretax Margin
-1,514.57%
Return on Equity
-215.59%
Return on Assets
-27.23%

Debt

Debt-to-Equity Ratio
0.20
Current Ratio
3.74
Quick Ratio
3.70

Sales & Book Value

Annual Sales
$3.84 million
Price / Sales
0.00
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($0.70) per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
28,599,000
Free Float
28,013,000
Market Cap
$90.80 million
Optionable
No Data
Beta
0.97
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

This page (NASDAQ:OCX) was last updated on 8/30/2025 by MarketBeat.com Staff
From Our Partners